TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01777243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852
Description: Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852
Description: Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
Study: NCT04672512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet for oral administration
Study: NCT01812382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Microdialysis
Description: After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
Study: NCT02183870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg crizotinib bid until end of treatment
Study: NCT04139915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactolisib
Description: TORC1 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT00323713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low protein diet
Description: 0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low protein diet
Description: 0.6 g of protein per kilo of body weight per day
Study: NCT02479997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioisotope
Description: Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioisotope
Description: Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
Study: NCT01269814

Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Gastroscopy
Study: NCT03394261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
Study: NCT00507975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine versus placebo
Description: The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine versus placebo
Description: The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
Study: NCT04509414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
Study: NCT02538718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YTP(Ritodrine)
Study: NCT04575259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Oral capsules
Study: NCT02601105

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Cream
Description: Lipoderm Cream alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella Asiatica Cream
Description: 1% Centella Asiatica in lipoderm
Study: NCT01107106

Intervention type: DRUG
Intervention: ellaOne® (ulipristal acetate)
Description: one single oral dose (30 mg tablet)

Intervention type: DRUG
Intervention: ellaOne® (ulipristal acetate)
Description: one single oral dose (30 mg tablet)
Study: NCT00742898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-targeted opt-out rapid HIV screening
Description: Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-targeted opt-out rapid HIV screening
Description: Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
Study: NCT02676440

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: F13/T38

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: M26
Study: NCT01750177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Television Viewing before mealtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Playing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting quietly
Study: NCT00978497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598
Description: oral 200mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598
Description: oral 400mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon
Description: 180 μg dose via subcutaneous injection weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: 180 μg dose via subcutaneous injection weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: 180 μg dose via subcutaneous injection weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
Study: NCT01457833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBV implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBV implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
Study: NCT01259440

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Teleconferencing Care
Description: The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Consists of one week telephone call and one month clinic visit
Study: NCT04574661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Occlusion
Description: Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
Study: NCT02639078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0714
Description: One time dosing in capsule formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: One time dosing in capsule formulation
Study: NCT02913170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nattokinase

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03128788

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
Study: NCT04106713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Psychotherapy
Description: The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy (iCBT)
Description: The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (group CBT)
Description: The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
Study: NCT01887990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: single dose IV 0.2 mg/kg ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: single dose IV 0.2 mg/kg ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline infusion
Study: NCT00997932

Intervention type: DRUG
Group type: OTHER
Intervention: Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration
Description: Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
Study: NCT05255198

Intervention type: PROCEDURE
Intervention: Anterior versus lateral approach to hip joint

Intervention type: PROCEDURE
Intervention: Anterior versus lateral approach to hip joint
Study: NCT03333083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (1200 mg once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (300 mg once a day)
Study: NCT02966600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Description: The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The control group followed its usual weekly physical activity routine
Study: NCT04228900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized plan for improvement of nutrition
Description: For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systematic drug review
Description: Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
Study: NCT03667599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care
Description: This is the interventional arm where patients receive the transplant care in their homes.
Study: NCT02179710

Intervention type: BEHAVIORAL
Intervention: Adherence dashboard motivational interviewing
Description: These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
Study: NCT00932555

Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients under daily life treatment receiving Kogenate according to local drug information.
Study: NCT03214250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Administer intravenously once every 28-day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Administer intravenously once every 28-day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administer intravenously twice every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administer intravenously twice every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer intravenously on 3 times every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer intravenously on 3 times every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer intravenously on 3 times every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer intravenously 3 times every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer intravenously 3 times every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer intravenously 3 times every 28-day cycle
Study: NCT01347177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia-based adhesive bridge
Description: Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal-based adhesive bridge
Description: The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
Study: NCT02554552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY1201 2ml
Description: YY1201 2ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2ml
Description: phosphate buffered saline 2ml
Study: NCT01192035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz or Nevirapine
Description: 2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count \>250 cells/mm3. Females beyond childbearing age will be treated with efavirenz.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: 2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
Study: NCT04936659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromodulation
Description: Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
Study: NCT02554552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY1201 3ml
Description: YY1201 2ml